Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

EPRX

Eupraxia Pharmaceuticals Inc

Mar 20 • 04:00PM ET

7.10

-0.50 -6.58 %

Healthcare • Biotechnology • Canada • NASD

Peers: GILD VRTX AMGN BIIB REGN INCY NBIX EXEL IONS BMRN

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-0.99	Insider Own	23.12%	Shs Outstand	51.94M	Perf Week	-3.53%
Market Cap	436.65M	Forward P/E	-	EPS next Y	-0.61	Insider Trans	0.00%	Shs Float	47.28M	Perf Month	-12.56%
Enterprise Value	384.38M	PEG	-	EPS next Q	-0.18	Inst Own	27.59%	Short Float	4.19%	Perf Quarter	12.88%
Income	-41.11M	P/S	-	EPS this Y	22.82%	Inst Trans	3.05%	Short Ratio	8.67	Perf Half Y	17.55%
Sales	0.00M	P/B	7.05	EPS next Y	11.36%	ROA	-63.71%	Short Interest	1.98M	Perf YTD	-5.96%
Book/sh	1.01	P/C	5.42	EPS next 5Y	-0.13%	ROE	-66.83%	52W High	9.32 -23.82%	Perf Year	81.59%
Cash/sh	1.31	P/FCF	-	EPS past 3/5Y	-2.38% -34.75%	ROIC	-50.06%	52W Low	2.68 164.92%	Perf 3Y	143.15%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	6.26% 5.38%	Perf 5Y	-
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	-31.19%	Oper. Margin	-	ATR (14)	0.44	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	15.12	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	35.21	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	15.12	EPS Q/Q	-58.38%	SMA20	-9.36%	Beta	1.71	Target Price	14.37
Payout	-	Debt/Eq	0.00	Sales Q/Q	-	SMA50	-13.92%	Rel Volume	1.13	Prev Close	7.60
Employees	-	LT Debt/Eq	0.00	Earnings	Mar 13 BMO	SMA200	12.51%	Avg Volume	228.34K	Price	7.10
IPO	Aug 03, 2021	Option/Short	No / Yes	EPS/Sales Surpr.	-85.75% -	Trades		Volume	258,103	Change	-6.58%

Date	Action	Analyst	Rating Change	Price Target Change
Jul-24-25	Initiated	Cantor Fitzgerald	Overweight	$11
Jun-26-25	Initiated	H.C. Wainwright	Buy	$12
Jun-16-25	Initiated	Canaccord Genuity	Speculative Buy
Feb-21-25	Initiated	Craig Hallum	Buy	$12
Nov-14-24	Initiated	Rodman & Renshaw	Buy	$9

Mar-17-26 07:00AM	Eupraxia Pharmaceuticals Reports Six-Month Symptom Data from the Highest Dose Cohort in its Ongoing Phase 1b/2a RESOLVE Trial in Eosinophilic Esophagitis (GlobeNewswire)
Mar-12-26 09:03PM	Eupraxia Pharmaceuticals Reports Fourth Quarter 2025 Financial Results (GlobeNewswire)
Feb-20-26 03:10PM	Eupraxia Pharmaceuticals Announces Closing of US$63.2 Million Public Offering Including Full Exercise of Underwriter Option (GlobeNewswire)
Feb-19-26 02:18AM	Eupraxia Pharmaceuticals Announces Pricing of US$55 Million Public Offering of Common Shares and Pre-Funded Warrants (GlobeNewswire)
Feb-18-26 04:01PM	Eupraxia Pharmaceuticals Announces Proposed Public Offering (GlobeNewswire)
01:10PM	Loading…
Jan-08-26 01:10PM	Eupraxia Trial Data Shows Lasting Tissue Healing In Patients With Inflamed Esophagus (Benzinga) +19.14%
07:34AM	Eupraxia Pharmaceuticals Reports Positive Tissue Health Data from its Ongoing RESOLVE Trial in Eosinophilic Esophagitis Demonstrating Near-Complete Improvement on Biopsy (GlobeNewswire)
Dec-04-25 10:09PM	Analysts See More Than 77% Upside for Eupraxia Pharmaceuticals (EPRX), Here's Why (Insider Monkey) +6.98%
Nov-14-25 09:55AM	Wall Street Analysts Think Eupraxia Pharmaceuticals Inc. (EPRX) Could Surge 75.08%: Read This Before Placing a Bet (Zacks)
Nov-13-25 05:00PM	Eupraxia Pharmaceuticals Reports Additional 52-week Follow-up Data from the RESOLVE Trial in Eosinophilic Esophagitis (EoE) Demonstrating Consistent Results after Dosing with EP-104GI (GlobeNewswire)
Nov-04-25 04:39PM	Eupraxia Pharmaceuticals Reports Third Quarter 2025 Financial Results (GlobeNewswire) -10.51%
Oct-22-25 09:40AM	Is Elanco Animal Health (ELAN) Stock Outpacing Its Medical Peers This Year? (Zacks)
Oct-14-25 12:00PM	Eupraxia Pharmaceuticals Inc. (EPRX) is a Great Momentum Stock: Should You Buy? (Zacks)
12:00PM	Eupraxia Pharmaceuticals Inc. (EPRX) Upgraded to Buy: Here's Why (Zacks)
09:55AM	Wall Street Analysts Believe Eupraxia Pharmaceuticals Inc. (EPRX) Could Rally 85.12%: Here's is How to Trade (Zacks)
05:00PM	Loading…
Sep-29-25 05:00PM	Eupraxia Pharmaceuticals Announces Positive Data from Highest-Dose Cohort in the Ongoing RESOLVE Trial in Eosinophilic Esophagitis, and Plans for Expansion of EP-104GI Development Programs (GlobeNewswire)
Sep-24-25 08:54AM	Eupraxia Pharmaceuticals Announces Closing of US$80.5 Million Public Offering Including Full Exercise of Underwriter Option (GlobeNewswire)
Sep-22-25 10:42PM	Eupraxia Pharmaceuticals Announces Pricing of US$70 Million Public Offering of Common Shares (GlobeNewswire) +11.58% -14.89%
04:01PM	Eupraxia Pharmaceuticals Announces Proposed Public Offering of Common Shares (GlobeNewswire)
Sep-02-25 08:00AM	First Set of 1-Year Clinical Results from RESOLVE Trial in Eosinophilic Esophagitis (EoE), Durable and Sustained Symptom & Tissue Responses after Dosing with EP-104GI (GlobeNewswire)
Aug-12-25 04:25PM	Eupraxia Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Update (GlobeNewswire)
Jul-22-25 05:17PM	Eupraxia Pharmaceuticals Invited to Present at Upcoming Investor Conferences (GlobeNewswire)
Jul-08-25 07:00AM	Eupraxia Doses First Patient in Phase 2b Placebo-Controlled Portion of EP-104GI RESOLVE Trial in Eosinophilic Esophagitis (GlobeNewswire)
Jun-02-25 06:30PM	Eupraxia Pharmaceuticals Announces Voting Results from Annual General and Special Meeting of Shareholders (GlobeNewswire)
May-15-25 05:00PM	Bear-Pit Session Highlights Peterson Capitals Canada Growth Conference in Montreal (GlobeNewswire)
May-07-25 02:00PM	Eupraxia Pharmaceuticals to Host Virtual KOL Event to Discuss the Phase 1b/2a RESOLVE Study of EP-104GI for the Treatment of Eosinophilic Esophagitis (EoE) on May 9, 2025 (GlobeNewswire) -6.77%
May-06-25 06:00PM	Eupraxia Pharmaceuticals Reports First Quarter 2025 Financial Results (GlobeNewswire)
May-05-25 07:00AM	Eupraxia Pharmaceuticals Announces Sustained Positive Treatment Outcomes in Patients with Eosinophilic Esophagitis (EoE) After Nine Months of Receiving EP-104GI (GlobeNewswire)
Apr-24-25 05:00PM	Eupraxia Pharmaceuticals to Present at Investor and Scientific Conferences in April and May (GlobeNewswire)
Mar-20-25 05:32PM	Eupraxia Pharmaceuticals Reports Fourth Quarter 2024 Financial Results (PR Newswire)
07:00AM	Loading…
Feb-25-25 07:00AM	Eupraxia Pharmaceuticals Announces Positive Data from RESOLVE Phase 1b/2a Trial of EP-104GI for Treatment of Eosinophilic Esophagitis (PR Newswire) +10.28%
Feb-22-25 09:05AM	Craig-Hallum starts Eupraxia at Buy, sees significant upside potential (TipRanks)
Feb-18-25 07:00AM	Eupraxia Pharmaceuticals Announces CFO Succession (PR Newswire)
Nov-20-24 07:00AM	Eupraxia's DiffuSphere Technology Demonstrates Targeted Drug Release while Minimizing Systemic Exposure for a Period of More Than Six Months (PR Newswire) +10.43%
Nov-14-24 05:00PM	Eupraxia Pharmaceuticals to Present at American College of Rheumatology Convergence 2024 Annual Meeting (PR Newswire) +7.96%
Nov-13-24 05:00PM	Eupraxia Pharmaceuticals' CEO Dr. James Helliwell to Participate in Webinar Event, 'Eosinophilic Esophagitis: The Emerging Digestive Disorder Frequently Misdiagnosed', on November 15, 2024 (PR Newswire)
Nov-12-24 05:56PM	Eupraxia Pharmaceuticals Announces Positive Data from Fifth Cohort of RESOLVE Phase 1b/2a Trial of EP-104GI for Treatment of Eosinophilic Esophagitis (PR Newswire)
Nov-07-24 05:00PM	Eupraxia Pharmaceuticals Reports Third Quarter 2024 Financial Results (PR Newswire)
Oct-31-24 07:36PM	Eupraxia Pharmaceuticals Announces that it has Closed a Non-Brokered Private Placement of C$44.5 Million (PR Newswire)
Oct-28-24 07:00AM	Eupraxia Pharmaceuticals to Present at American College of Gastroenterology Annual Scientific Meeting 2024 (PR Newswire)
Oct-15-24 07:00AM	Lancet Rheumatology Publishes Phase 2b Data on Eupraxia Pharmaceuticals' EP-104IAR for the Treatment of Knee Osteoarthritis (PR Newswire)
Oct-10-24 07:00AM	Eupraxia Pharmaceuticals to Present at United European Gastroenterology Week 2024 (PR Newswire)
Oct-02-24 05:01PM	Eupraxia Pharmaceuticals Strengthens Senior Management Team (PR Newswire)
Sep-19-24 05:00PM	Eupraxia Pharmaceuticals to Present at 20th ISDE World Congress for Esophageal Diseases (PR Newswire)
Sep-11-24 07:00AM	Eupraxia Pharmaceuticals Announces Data from RESOLVE Phase 1b/2a Trial of EP-104GI for Treatment of Eosinophilic Esophagitis (PR Newswire)
Sep-04-24 07:00AM	Eupraxia Pharmaceuticals to Present at the H.C. Wainwright 26th Annual Global Investment Conference (PR Newswire) -5.77%
Aug-07-24 05:00PM	Eupraxia Pharmaceuticals Reports Second Quarter 2024 Financial Results (PR Newswire) +5.44%
Aug-02-24 07:00AM	Eupraxia Pharmaceuticals Announces New C$12 Million Convertible Debt Facility (PR Newswire) -10.14%
Jul-08-24 07:00AM	Eupraxia Pharmaceuticals to Present at Controlled Release Society 2024 Annual Meeting and Expo (PR Newswire)
Jul-03-24 05:00PM	Eupraxia Pharmaceuticals' CEO Dr. James Helliwell to Participate in Webinar Event, 'Exploring the Rapid Rise of Osteoarthritis' on July 9, 2024 (PR Newswire)
Jun-06-24 05:00PM	Eupraxia Pharmaceuticals Announces Voting Results from Annual General and Special Meeting of Shareholders (PR Newswire)
Jun-05-24 07:00AM	Eupraxia Pharmaceuticals to Present Data from the Phase 2 SPRINGBOARD Study in Osteoarthritis of the Knee at EULAR European Congress of Rheumatology 2024 (PR Newswire)
May-23-24 05:00PM	Eupraxia Pharmaceuticals Announces Expansion of RESOLVE Phase 1b/2a Trial of EP-104GI for Treatment of Eosinophilic Esophagitis (PR Newswire)
May-22-24 07:23AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday (InvestorPlace)
07:00AM	Eupraxia Pharmaceuticals to Host Virtual KOL Event on EP-104GI Clinical Development Program for Eosinophilic Esophagitis ('EoE') on May 29, 2024 (PR Newswire)
May-21-24 05:00PM	Eupraxia Pharmaceuticals Announces New Positive Data from RESOLVE Phase 1b/2a Trial of EP-104GI for Treatment of Eosinophilic Esophagitis (PR Newswire)
May-14-24 07:00AM	Eupraxia Pharmaceuticals to Present Initial Results from Ongoing Phase 1b Study of EP-104GI for the Treatment of Eosinophilic Esophagitis at Upcoming Digestive Disease Week Annual Meeting 2024 (PR Newswire)
May-08-24 05:03PM	Eupraxia Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate Update (PR Newswire)
May-02-24 07:00AM	Eupraxia Pharmaceuticals Announces Gastrointestinal Clinical Advisory Board (PR Newswire)
Apr-11-24 07:00AM	Eupraxia Pharmaceuticals Announces Upcoming Presentations at the Osteoarthritis Research Society International World Congress 2024 (PR Newswire) -6.34%
Apr-08-24 07:00AM	Eupraxia Pharmaceuticals To Present at Bloom Burton & Co. Healthcare Investor Conference (PR Newswire)
Apr-05-24 07:00AM	Eupraxia Pharmaceuticals Begins Trading on Nasdaq Today (PR Newswire)

Eupraxia Pharmaceuticals, Inc. operates as a drug delivery technology company in Canada. It delivers drugs into body compartments, such as the joint without any of the common issues with body compartment injections, such as systemic exposure. The firm focuses on arthritis, diabetic macular edema, and chronic pain programs. The company was founded by James A. Helliwell, John Salvatore Montalbano and Amanda Malone on May 12, 2011 and is headquartered in Victoria, Canada.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

EPRX

Eupraxia Pharmaceuticals Inc

Upgrade your FINVIZ experience